Spruce Biosciences

Graphic image of a pen signing a signature while two strangelooking business people cheer
Biotech

Spruce inks deal for BioMarin asset, plans 2026 approval filing

Spruce bagged rights to a former BioMarin rare disease candidate and outlined plans to seek accelerated FDA approval in the first half of next year.
Nick Paul Taylor Apr 15, 2025 10:29am
chop down cut tree chainsaw ax

Spruce drops only drug after 2nd hyperplasia phase 2 fail

Dec 11, 2024 5:00am
chop down cut tree chainsaw ax

Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail

Mar 14, 2024 8:27am
Parachute

Pfizer taps former CVS exec Denton for CFO role—Chutes & Ladders

Apr 15, 2022 9:30am
Parachute

Bind's ex-head Hirsch washes up at C4 as CEO—Chutes & Ladders

Sep 11, 2020 9:30am
Green traffic light

Spruce nets $88M to push rare disease drug into late-stage trial

Feb 20, 2020 9:55am